The prognosis of biliary tract cancers (BTC) after radical resection is still unsatisfactory.
However, the clinical value of adjuvant therapy remains controversial.
This retrospective study aimed to evaluate the clinical value of adjuvant chemotherapy and adjuvant chemoimmunotherapy in patients with BTC after radical resection.
